Regencell Bioscience Holdings Limited (RGC)

HK — Healthcare Sector
Peers: CYTK  MRUS  ATR  GRFS  ABVX  RYTM  STVN  AXSM  NUVL  MASI 

Automate Your Wheel Strategy on RGC

With Tiblio's Option Bot, you can configure your own wheel strategy including RGC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Regencell Bioscience: Extended Lock-Up Creates Significant Upside Potential
RGC
Published: March 06, 2026 by: Seeking Alpha
Sentiment: Positive

Regencell Bioscience Holdings Limited has surged 23,745% in 2025, reaching a $12b market cap despite having zero revenue. RGC's explosive upside is driven by float mechanics, with the founder and his wife locking up most of the free float. Recent SEC filings and a 35-for-1 reverse stock split have increased accessibility and meme stock potential, fueling further price momentum.

Read More
image for news Regencell Bioscience: Extended Lock-Up Creates Significant Upside Potential
These 3 Growth Stocks Won't Be This Cheap Forever
RGC, RGTI, RKLB
Published: February 19, 2026 by: 24/7 Wall Street
Sentiment: Positive

Finding top growth stocks with the kind of capital appreciation upside long-term investors are seeking is the name of the game for a solid majority of investors in the market right now.

Read More
image for news These 3 Growth Stocks Won't Be This Cheap Forever
This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)
RGC
Published: November 24, 2025 by: The Motley Fool
Sentiment: Neutral

Regencell Bioscience looks like a risky bet. It's generated zero revenue for several years in a row.

Read More
image for news This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regencell Bioscience Holdings Limited - RGC
RGC
Published: November 20, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regencell Bioscience Holdings Limited - RGC

About Regencell Bioscience Holdings Limited (RGC)

  • IPO Date 2021-07-16
  • Website https://www.regencellbioscience.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Yat-Gai Au
  • Employees 12
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.